01093.HK
CSPC Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 9.69
+0.78%Sep 1, 2026, 10:35 UTC
Shenzhen Sineuro Medical Technology Co., Ltd., a subsidiary of Sinomed, received a Class III medical device registration certificate from China's National Medical Products Administration for its delivery-type balloon dilation catheter, valid until August 30, 2031.
Source:Sep 1, 2026, 10:10 UTC
CSPC Pharmaceutical Group announced that its drug SYS6010 was again included in the National Medical Products Administration's Breakthrough Therapy Designation list for the treatment of recurrent or metastatic head and neck squamous cell carcinoma after failure of prior immunotherapy and platinum-based chemotherapy.
Aug 28, 2026, 08:47 UTC
CSPC Pharmaceutical Group announced the initiation of the Phase II clinical trial for its weight-loss drug SYH2069 at the first research center in China.
Source:Aug 28, 2026, 05:58 UTC
CSPC Pharmaceutical Group established a health innovation technology company in Shijiazhuang, with a business scope including medical device sales and pharmaceutical wholesale and retail.
Source:Aug 28, 2026, 02:07 UTC
Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.
Source:Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:Aug 27, 2026, 09:14 UTC
Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.
Aug 26, 2026, 10:38 UTC
CSPC Pharmaceutical Group announced that its PD-1/IL-15 bispecific fusion protein SYS 6090 (JMT108) received Fast Track designation from the U.S. FDA for the treatment of metastatic colorectal cancer patients with MSS or pMMR tumors.
Source:Aug 25, 2026, 11:16 UTC
CSPC Pharmaceutical Group received FDA approval to conduct clinical trials in the United States for its recombinant respiratory syncytial virus vaccine (SYS 6057).
Source:Aug 20, 2026, 10:07 UTC
Shiyao Jingfeng announced its first-half 2026 results, reporting a net profit of 5.8689 million yuan, turning around from a loss of 32.5674 million yuan in the same period last year.
Source:Aug 20, 2026, 06:48 UTC
Shares of CSPC Pharmaceutical Group surged over 15% in morning trading on August 20, 2026, driven by positive Phase 3 results of Moderna and Merck's personalized mRNA cancer therapy intismeran.
Source:Aug 20, 2026, 04:36 UTC
CSPC Pharmaceutical Group declared an interim dividend of HK$0.18 per share, an increase of 28.6% from HK$0.14 in the same period last year.
Source:Aug 20, 2026, 04:18 UTC
CSPC Pharmaceutical Group reported first-half revenue of 18.59 billion yuan, exceeding the market estimate of 14.63 billion yuan.
Aug 18, 2026, 13:58 UTC
China Securities Regulatory Commission Hunan Bureau ordered Ye Xianglun, a concert party of Ye Xiangwu (a shareholder holding over 5% of Shiyao Jingfeng), to buy back improperly reduced shares and remit the price difference to the listed company.
Source:Aug 18, 2026, 13:04 UTC
China's National Medical Products Administration accepted the new drug application for KN026 combined with HB1801 for first-line treatment of advanced breast cancer, developed by CSPC Group's subsidiary Jinmantebio and Alphamab Oncology, and granted priority review.
Source:Aug 18, 2026, 10:38 UTC
Shanghai Second Intermediate People's Court will conduct a second judicial auction of 2.5 million shares of Shiyao Jingfeng held by shareholder Ye Xiangwu from September 3 to 6, 2026, after the first auction failed.
Source:Aug 10, 2026, 10:58 UTC
Shijiazhuang Pharmaceutical Group's monkeypox mRNA vaccine SYS6037 injection, developed in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences, received US FDA approval to conduct clinical trials.
Source:Aug 5, 2026, 09:51 UTC
CSPC Group received a US$10 million milestone payment from AstraZeneca on 5 August 2026 under the strategic research and development collaboration agreement, related to AstraZeneca's exercise of the license option for one of the PCC projects.
Aug 5, 2026, 08:35 UTC
CSPC Group and AstraZeneca signed a joint venture contract to establish a joint venture.
Aug 4, 2026, 10:07 UTC
Alphamab Oncology and CSPC Pharmaceutical Group subsidiary Jinmantebio's new drug application for anlotinib combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer has been accepted by China's National Medical Products Administration and included in priority review.
Source:Jul 31, 2026, 10:03 UTC
CSPC Group announced that its recombinant respiratory syncytial virus vaccine (SYS 6057) has been approved by China's National Medical Products Administration to conduct clinical trials in China.
Source:Jul 30, 2026, 23:56 UTC
CSPC Pharmaceutical Group's wholly-owned subsidiary CSPC Zhongqi plans to enter into a second foreign exchange forward contract with Industrial and Commercial Bank of China to buy USD 90 million for RMB 612 million.
Source:Jul 28, 2026, 02:02 UTC
CSPC Pharmaceutical Group's marketing application for injectable sirolimus (albumin-bound) was accepted by the National Medical Products Administration and granted priority review.
Source:Jul 28, 2026, 01:38 UTC
Shiyao Group expects its interim comprehensive profit to be between 5.9 billion and 6.2 billion RMB.
Source:Jul 15, 2026, 02:58 UTC
China's National Medical Products Administration (CDE) granted breakthrough therapy designation to KN026 (Anni Tuo monoclonal antibody) combined with HB1801 for first-line treatment of HER2-positive breast cancer.
Source:
Page 1Next →